SkinBioTherapeutics plc
("SkinBioTherapeutics" or the "Company")
Results of AGM
29 December 2023 - SkinBioTherapeutics plc (AIM: SBTX or the "Company") announces that at the Company's Annual General Meeting, held today, all resolutions were duly passed.
Details of the proxy votes received on each resolution by the Company's Registrar are set out below:
| Resolution | For & Discretionary | Against | Withheld | ||||
|
|
| Number of votes | % | Number of votes | % | Number of votes | % |
| 01 | Ordinary resolution to receive and adopt the directors' and auditors' report and the financial statements for year ended 30 June 2023 | 43,029,848 | 96.78% | 1,413,649 | 3.18% | 17,051 | 0.04% |
| 02 | Ordinary resolution for Gravita Audit Limited to be re-appointed as the auditors of the Company until the next AGM | 42,677,600 | 95.99% | 448,075 | 1.01% | 1,334,873 | 3.00% |
| 03 | Ordinary resolution for the Directors' to be authorised to fix the auditors' remuneration | 42,958,431 | 96.62% | 186,707 | 0.42% | 1,315,410 | 2.96% |
| 04 | Ordinary resolution for Stuart Ashman to be re-elected as a Director of the Company | 39,303,678 | 88.40% | 2,636,183 | 5.93% | 2,520,687 | 5.67% |
| 05 | Ordinary resolution for Martin Hunt to be re-elected as a Director of the Company | 39,991,885 | 89.95% | 2,248,346 | 5.06% | 2,220,317 | 4.99% |
| 06 | Ordinary resolution for Dr Catherine Prescott to be re-elected as a Director of the Company | 40,063,946 | 90.11% | 3,072,834 | 6.91% | 1,323,768 | 2.98% |
| 07 | Ordinary resolution for Danielle Bekker to be re-elected as a Director of the Company | 42,059,615 | 94.60% | 972,653 | 2.19% | 1,428,280 | 3.21% |
| 08 | Ordinary resolution for Manprit Singh Randhawa to be re-elected as a Director of the Company | 39,716,379 | 89.33% | 2,419,340 | 5.44% | 2,324,829 | 5.23% |
| 09 | Ordinary resolution to authorise the directors to allot shares | 42,030,813 | 94.54% | 1,096,351 | 2.47% | 1,333,384 | 3.00% |
| 10 | Special resolution to authorise the directors to disapply pre-emption rights | 42,285,656 | 95.11% | 822,045 | 1.85% | 1,352,847 | 3.04% |
| 11 | Special resolution to authorise the directors to disapply pre-emption rights in relation to an acquisition or other capital investment | 42,302,981 | 95.15% | 804,720 | 1.81% | 1,352,847 | 3.04% |
-Ends-
For more information, please contact:
| SkinBioTherapeutics plc
| Tel: +44 (0) 191 495 7325 |
| Cavendish Capital Markets Limited (Nominated Adviser & Broker) Giles Balleny, Dan Hodkinson Charlie Combe (Broking) Dale Bellis, Tamar Cranford-Smith (Sales) | Tel: +44 (0) 20 7220 0500
|
| Instinctif Partners (financial press) | Tel: +44 (0) 20 7457 2020 SkinBioTherapeutics @instinctif.com |
Notes to Editors
About SkinBioTherapeutics plc
SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by Professor Catherine O'Neill and Professor Andrew McBain.
The Company is targeting a number of skin healthcare sectors, the most advanced of which are cosmetic skincare and food supplements to modulate the immune system by harnessing the gut-skin axis. In each area SkinBioTherapeutics plans to exemplify its technology through human studies. The Company's first product, AxisBiotix-Ps?, a food supplement to address the symptoms of mild to moderate psoriasis.
The Company listed on AIM in April 2017 and is based in Newcastle, UK. For more information, visit: www.skinbiotherapeutics.com and www.axisbiotix.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.